Mircera could finally come to market a year later, when Amgen's intellectual property expires.

FORBES: Amgen's Next Opponents

In 2005, Amgen sued Roche, saying Mircera infringed its patents.

FORBES: Magazine Article

Amgen will ask for an injunction on Mircera being sold.

FORBES: Amgen's Next Opponents

Joel Sendek, an analyst at Lazard Capital Markets who says to sell Amgen's stock, argues that Mircera will still hurt Amgen internationally and that sales of anemia drugs are still going to be slower than Wall Street expects.

FORBES: Magazine Article